The present disclosure relates to a method of purifying a plasma protein from a plasma sample or a plasma fraction thereof, comprising contacting the plasma sample or plasma fraction thereof with a surfactant; one or more surfactant adsorbers and/or a chromatography step; compositions comprising the purified plasma sample or plasma fraction thereof and uses thereof.
C07K 16/06 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies from serum
B01D 15/26 - Selective adsorption, e.g. chromatography characterised by the separation mechanism
B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
C07K 1/16 - ExtractionSeparationPurification by chromatography
C07K 1/22 - Affinity chromatography or related techniques based upon selective absorption processes
B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
C07K 1/113 - General processes for the preparation of peptides by chemical modification of precursor peptides without change of the primary structure
Disclosed herein is a method of purifying proteins, in particular hemopexin, comprising passing a solution comprising hemopexin and other proteins through a mixed-mode cation exchange chromatography resin under conditions that promote selective binding of hemopexin to the resin, and eluting the bound hemopexin from the resin. The present disclosure also extends to compositions comprising purified hemopexin and uses thereof.
C07K 1/16 - ExtractionSeparationPurification by chromatography
C07K 1/34 - ExtractionSeparationPurification by filtration, ultrafiltration or reverse osmosis
C07K 1/36 - ExtractionSeparationPurification by a combination of two or more processes of different types
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
The present disclosure relates to a method of determining the concentration of a plasma protein in a sample using fluorescence polarization, wherein the sample is in an assay solution comprising a neutral hydrophilic polymer.
The present invention relates broadly to methods for the isolation of proteins from plasma or fractions thereof using continuous chromatography and Raman spectroscopic analysis.
The present disclosure relates to methods of detecting a target ligand in a sample, wherein the target ligand is capable of inducing oligomerization and/or cross-linking of the target ligand's receptor, and uses of the method thereof.
The invention relates to haptoglobin or a nucleic acid encoding haptoglobin for use in treating or preventing of exaggerated erectile response and/or preventing permanent erectile dysfunction. In addition, the invention relates a pharmaceutical composition for use in treating or preventing exaggerated erectile response and/or preventing permanent erectile dysfunction, wherein the pharmaceutical composition comprises an adeno-associated viral (AAV) vector with a transgene encoding a haptoglobin gene. The exaggerated erectile response may be priapism, for example priapism associated with sickle cell disease (SCD).
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 15/00 - Drugs for genital or sexual disordersContraceptives
A61P 15/10 - Drugs for genital or sexual disordersContraceptives for impotence
The present invention relates generally to a stable liquid formulation of purified hemopexin comprising: (a) a hemopexin content of at least 50 mg/mL; (b) at least 15 mM phosphate buffer; (c) a pH from 5.8 to 8; and (d) at least 50 mM sodium chloride; and uses thereof.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
9.
A MANUFACTURING PROCESS FOR ALBUMIN INVOLVING A HEATING STEP
The present disclosure relates to methods of separating solids from liquids, and more particularly to a method of separating solids from liquids in the purification of biological materials, such as recombinant proteins and/or plasma proteins. The present disclosure also relates to a filtration system for solid-liquid separation of a feed suspension (310) comprising a solid suspended in a filtrate (320), where at least one of the filtrate and the solid comprise a protein-of-interest.
The present disclosure relates generally to methods of treating or preventing an adverse secondary neurological outcome in a subject following a haemorrhagic stroke accompanied by extravascular erythrolysis and release of cell-free heme and/or cell-free haemoglobin (Hb) into a cerebral spinal fluid (CSF), the method comprising exposing the CSF of a subject in need thereof to a therapeutically effective amount of hemopexin (Hx) and for a period of time sufficient to allow the Hx to form a complex with, and thereby neutralise, the cell-free heme and, optionally, exposing the CSF of the subject to a therapeutically effective amount of haptoglobin (Hp) and for a period of time sufficient to allow the Hp to form a complex with, and thereby neutralise, the cell-free Hb.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/00 - Drugs for disorders of the nervous system
The present invention relates to an immunoglobulin therapy. In particular, an immunoglobulin therapy for treating CIDP with non-axonal damage or mild axonal damage is provided.
The present invention relates to an expression system for producing a recombinant haptoglobin (Hp) beta chain, or a haemoglobin-binding fragment thereof, recombinant Hp molecules and uses thereof for treating and/or preventing a condition associated with cell-free haemoglobin (Hb).
The invention relates to methods for determining the concentration of an analyte in a sample obtained from processing of blood-derived plasma, the method comprising applying a light source in the near-infrared spectrum to a test sample obtained from processing of blood-derived plasma; measuring reflectance, transmission or transflectance of the test sample over a range of near-infrared wavelengths, thereby generating test wavelength spectra, comparing the test wavelength spectra with reference wavelength spectra obtained from reference samples having known concentrations of the analyte, to determine the concentration of the analyte in the sample. The invention also relates to the development of a multivariate model for use in determining the concentration of an analyte, for example, total protein or alcohol (e.g. ethanol).
G01N 21/359 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light
G01N 21/27 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
G01N 33/487 - Physical analysis of biological material of liquid biological material
The invention relates to liquid aqueous compositions comprising a polyclonal immunoglobulin (Ig) and a stabilizer, wherein the stabilizer comprises serine, as well as to methods for generating an aerosol by nebulization of a composition comprising a polyclonal immunoglobulin (Ig) and serine.
The present invention relates to haptoglobin (Hp), and optionally hemopexin (Hx), for use in the treatment of traumatic brain injury (TBI) and in particular in the treatment or prevention of a secondary brain injury in a subject suffering from a TBI.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
19.
HAPTOGLOBIN FOR USE IN TREATING TRAUMATIC BRAIN INJURY (TBI)
The present invention relates to haptoglobin (Hp), and optionally hemopexin (Hx), for use in the treatment of traumatic brain injury (TBI) and in particular in the treatment or prevention of a secondary brain injury in a subject suffering from a TBI.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
20.
METHODS OF SANITIZING AND/OR REGENERATING A CHROMATOGRAPHY MEDIUM
The present disclosure relates to methods of sanitizing a chromatography medium. The present disclosure also relates to regenerating the chromatography medium.
B01D 15/20 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
The invention relates to methods for determining the concentration of an analyte in a sample (such as a sample obtained from the purification or substantial purification of a therapeutic protein, including a blood-plasma-derived therapeutic protein), the method comprising applying a light source in the near-infrared spectrum to a test sample obtained from the purification or substantial purification of the protein; measuring transmission or transflectance of the test sample over a range of near-infrared wavelengths, thereby generating test wavelength spectra, comparing the test wavelength spectra with reference wavelength spectra obtained from reference samples having known concentrations of the analyte, to determine the concentration of the analyte in the sample. The invention also relates to the development of a multivariate model for use in determining the concentration of an analyte, for example, total protein or a stabiliser (e.g. an amino acid, amino acid derivative, or non-amino acid). Further, the invention relates to methods of formulating therapeutics proteins, and formulations, compositions or preparations prepared by methods of the invention.
G01N 21/3577 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing liquids, e.g. polluted water
G01N 21/359 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light
22.
METHOD OF PURIFYING IMMUNOGLOBULIN G AND USES THEREOF
The present disclosure relates to methods of purifying immunoglobulin G (IgG) and other proteins, such as albumin, from plasma or a fraction thereof using an affinity chromatography resin comprising a ligand capable of specifically binding to a CH3 domain of human IgG. The present disclosure also relates to formulation and uses of plasma protein product produced from the method.
The present invention relates to a method for sterile filtration of an albumin-containing aqueous solution (2), wherein the method comprises filtering the solution (2) with at least one filter (3) to obtain a filtrate (1), wherein the at least one filter (3) is conditioned prior to filling the filtrate (1) into at least one container (10, 10') by purging the at least one filter (3) with a quantity (5) of the albumin-containing aqueous solution (2) i) at a differential pressure across the respective filter (3) of at most 1 bar and/or ii) by means of pressure filtration, wherein the filtrate (1) is maintained in the outlet (4) of the respective filter (3) at a back pressure of at least 0.5 bar is maintained.
The present invention pertains to a pharmaceutical product comprising a polyclonal immunoglobulin solution in a pre-filled polymer syringe in secondary packaging comprising an oxygen scavenger.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
B65D 75/36 - Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages
B65D 81/26 - Adaptations for preventing deterioration or decay of contentsApplications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, fluids, e.g. exuded by contentsApplications of corrosion inhibitors or desiccators
B65D 81/30 - Adaptations for preventing deterioration or decay of contentsApplications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants by excluding light or other outside radiation
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
The present disclosure relates to methods of isolating a protein-of-interest enriched solution, such as an immunoglobulin G (IgG), and a plurality of protein-of-interest depleted fractions from a protein mixture, such as plasma or a fraction thereof, using continuous chromatography. The present disclosure also relates to a continuous chromatography system for separating a protein-of-interest from a protein mixture, formulations and uses of the purified products thereof.
The present invention relates to improved industrial scale processes for removing metal cations, such as copper, from blood plasma derived albumin products and pharmaceutical compositions derived therefrom. The albumin sample is contacted with a ligand for binding to or sequestering the metal cations, said ligand is a chelating agent, most preferably a biodegradable chelating agent, or a chelating resin, most preferably a cation-exchange chelating resin.
This disclosure pertains to the use of immunoglobulin preparations, such as liquid polyclonal immunoglobulin preparations for treatment of systemic sclerosis (SSc), such as diffuse cutaneous systemic sclerosis (dcSSc) and limited cutaneous systemic sclerosis (lcSSc). In some embodiments, the preparations are administered subcutaneously (SCIG preparations). 0 In some embodiments, the preparations have a high concentration of immunoglobulin, such as 15-30% or 16-22% w/v.
The invention relates to a method for the purification of immunoglobulin and/or albumin from a sample of plasma, the method comprising mixing a sample of plasma with a medium chain fatty acid, and recovering the soluble immunoglobulin from the mixture.
The present disclosure relates to methods of identifying and reducing anti-Fc epsilon Receptor I (FcεRI) immunoglobulins (Ig) associated with adverse reactions from plasma or a fraction thereof, formulations and uses of the anti-FcεRI Ig reduced plasma protein product thereof.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
31.
METHODS OF IDENTIFYING IMMUNOGLOBULIN ASSOCIATED WITH ADVERSE REACTIONS
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immuno deficiency disorders; intravenous immunoglobulins for use in the treatment of immuno deficiency disorders and in immune replacement therapy; Pharmaceutical preparations for the treatment of dermatomyositis, inflammatory diseases and inflammatory conditions, muscle conditions and skin conditions; pharmaceutical preparations for the treatment of skin rash, weight loss, fever, lung conditions, light sensitivity, calcium deposits, and cardiovascular conditions; pharmaceutical preparations for the treatment of inflammatory myopathy and muscular conditions
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immuno deficiency disorders; intravenous immunoglobulins for use in the treatment of immuno deficiency disorders and in immune replacement therapy; Pharmaceutical preparations for the treatment of dermatomyositis, inflammatory diseases and inflammatory conditions, muscle conditions and skin conditions; pharmaceutical preparations for the treatment of skin rash, weight loss, fever, lung conditions, light sensitivity, calcium deposits, and cardiovascular conditions; pharmaceutical preparations for the treatment of inflammatory myopathy and muscular conditions
34.
PROCESS FOR ISOLATING PLASMINOGEN FROM A BLOOD PLASMA FRACTION
The present invention relates to a method for isolating plasminogen from a blood plasma fraction comprising dispersing a precipitate of a blood plasma fraction containing plasminogen in a basic aqueous buffer, separating solid parts thereof and removing at least parts of other proteins, and extracting the plasminogen with an acidic aqueous buffer.
The invention provides a process for reducing protease activity in a solution comprising anti-D immunoglobulin G comprising the steps of i) providing a solution comprising anti-D immunoglobulin G; ii) contacting said solution with aluminium hydroxide gel at a pH of 4.70 to 4.90; and iii) separating the solution from the solid components. The use of these conditions reduces protease activity, preferably without reducing yield of anti-D immunoglobulin G.
C07K 16/06 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies from serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
36.
METHOD OF PURIFYING HEMOPEXIN USING MIXED-MODE CHROMATOGRAPHY
Disclosed herein is a method of purifying proteins, in particular hemopexin, comprising passing a solution comprising hemopexin and other proteins through a mixed-mode cation exchange chromatography resin under conditions that promote selective binding of hemopexin to the resin, and eluting the bound hemopexin from the resin. The present disclosure also extends to compositions comprising purified hemopexin and uses thereof.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 1/16 - ExtractionSeparationPurification by chromatography
C07K 1/36 - ExtractionSeparationPurification by a combination of two or more processes of different types
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Promoting awareness of immunoglobulin, immunodeficiency and neurological disorders, its treatment and its impact on patients, patient families, caregivers and/or healthcare professionals to patients, caregivers and/or healthcare professionals Healthcare and healthcare information services, namely, providing information concerning immunoglobulin, immunodeficiency and neurological disorders, their treatment and their impact on patients, patient families, caregivers and/or healthcare professionals
39.
CD91 POLYPEPTIDE FOR USE IN DETECTING HEMOPEXIN:HEME COMPLEX
The present invention relates to the use of a CD91 polypeptide for detection and quantification of a hemopexin:heme complex in a biological sample, to the use of a CD91 polypeptide for separation of a hemopexin:heme complex from a biological sample and to the monitoring of a hemolysis treatment using a CD91 polypeptide.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The invention relates to haptoglobin or a nucleic acid encoding haptoglobin for use in treating or preventing of exaggerated erectile response and/or preventing permanent erectile dysfunction. In addition, the invention relates a pharmaceutical composition for use in treating or preventing exaggerated erectile response and/or preventing permanent erectile dysfunction, wherein the pharmaceutical composition comprises an adeno-associated viral (AAV) vector with a transgene encoding a haptoglobin gene. The exaggerated erectile response may be priapism, for example priapism associated with sickle cell disease (SCD).
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Promoting awareness of immunoglobulin, immunodeficiency and neurological disorders, its treatment and its impact on patients, patient families, caregivers and/or healthcare professionals to patients, caregivers and/or healthcare professionals Healthcare and healthcare information services, namely, providing information concerning immunoglobulin, immunodeficiency and neurological disorders, their treatment and their impact on patients, patient families, caregivers and/or healthcare professionals
43.
METHOD OF MONITORING PARAMETERS IN TURBID SOLUTIONS
The invention relates to methods for determining the concentration of an analyte in a sample obtained from processing of blood-derived plasma, the method comprising applying a light source in the near-infrared spectrum to a test sample obtained from processing of blood-derived plasma; measuring reflectance, transmission or transflectance of the test sample over a range of near-infrared wavelengths, thereby generating test wavelength spectra, comparing the test wavelength spectra with reference wavelength spectra obtained from reference samples having known concentrations of the analyte, to determine the concentration of the analyte in the sample. The invention also relates to the development of a multivariate model for use in determining the concentration of an analyte, for example, total protein or alcohol (e.g. ethanol).
G01N 21/31 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
G01N 21/359 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
The present disclosure relates to methods of sanitizing a chromatography medium. The present disclosure also relates to regenerating the chromatography medium.
B01D 15/20 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
B01J 20/286 - Phases chemically bonded to a substrate, e.g. to silica or to polymers
The present disclosure relates to methods of sanitizing a chromatography medium. The present disclosure also relates to regenerating the chromatography medium.
B01D 15/20 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical preparations for the treatment of immunodeficiency disorders; Pharmaceutical preparations for the treatment of chronic inflammatory demyelinating polyneuropathy and primary immunodeficiency; pharmaceutical preparations in the nature of intravenous immunoglobulins for use in the treatment of immunodeficiency disorders and in immune replacement therapy Surgical and medical apparatus and instruments for subcutaneous treatment, namely, for the administration of subcutaneous therapy; Medical devices for the administration of subcutaneous therapy for use in treating immunodeficiency disorders; Surgical instruments for use in the administration of subcutaneous medicine; medical instruments for use in the administration of subcutaneous infusion of medicine; Medical apparatus and instruments for use in subcutaneous medical procedures; Medical devices for the administration of subcutaneous therapy, namely, medical devices for accessing subcutaneous structures of the human body for the purpose of administering medical treatment
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of cardiovascular diseases, illnesses, and conditions; Pharmaceutical preparations for infusion conditions, namely cancers, autoimmune diseases, Crohn's disease, multiple sclerosis, serious infectious diseases, namely respiratory infections, eye infections, and severe dehydration; pharmaceutical preparations for the treatment of cardiovascular and blood disorders, namely, novel, plasma derived apolipoprotein A-I conditions while undergoing infusion therapy; pharmaceutical preparations in the nature of intravenous fluids used for the delivery of pharmaceutical preparations for novel apolipoprotein A-I infusion therapy to potentially reduce the risk of recurrent major adverse cardiovascular events, MACE, in patients within 90 days of an acute myocardial infarction, AMI, with a sustained benefit for 365 days; Pharmaceutical preparations for the treatment of acute myocardial infarction (AMI) being blood disorders; pharmaceutical preparations for treating of blood disorders and autoimmune diseases and disorders, namely, von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema (HAE), fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; Pharmaceutical preparations for the treatment and prevention of blood and blood bleeding disorders; pharmaceutical preparations for the treatment of hemophilia blood disorders; pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia blood disorders; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of blood diseases and disorders, respiratory diseases and disorders, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome (ARDS); pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and interstitial lung disease (ILD); Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema (HAE); Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema (HAE), respiratory diseases, acute respiratory distress syndrome (ARDS), Idiopathic Pulmonary Fibrosis (IPF) and interstitial lung disease (ILD);
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of cardiovascular diseases, illnesses, and conditions; Pharmaceutical preparations for infusion conditions, namely cancers, autoimmune diseases, Crohn's disease, multiple sclerosis, serious infectious diseases, namely respiratory infections, eye infections, and severe dehydration; pharmaceutical preparations for the treatment of cardiovascular and blood disorders, namely, novel, plasma derived apolipoprotein A-I conditions while undergoing infusion therapy; pharmaceutical preparations in the nature of intravenous fluids used for the delivery of pharmaceutical preparations for novel apolipoprotein A-I infusion therapy to potentially reduce the risk of recurrent major adverse cardiovascular events, MACE, in patients within 90 days of an acute myocardial infarction, AMI, with a sustained benefit for 365 days; Pharmaceutical preparations for the treatment of acute myocardial infarction (AMI) being blood disorders; pharmaceutical preparations for treating of blood disorders and autoimmune diseases and disorders, namely, von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema (HAE), fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; Pharmaceutical preparations for the treatment and prevention of blood and blood bleeding disorders; pharmaceutical preparations for the treatment of hemophilia blood disorders; pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia blood disorders; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of blood diseases and disorders, respiratory diseases and disorders, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome (ARDS); pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and interstitial lung disease (ILD); Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema (HAE); Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema (HAE), respiratory diseases, acute respiratory distress syndrome (ARDS), Idiopathic Pulmonary Fibrosis (IPF) and interstitial lung disease (ILD);
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of cardiovascular diseases, illnesses, and conditions; Pharmaceutical preparations for infusion conditions, namely cancers, autoimmune diseases, Crohn's disease, multiple sclerosis, serious infectious diseases, namely respiratory infections, eye infections, and severe dehydration; pharmaceutical preparations for the treatment of cardiovascular and blood disorders, namely, novel, plasma derived apolipoprotein A-I conditions while undergoing infusion therapy; pharmaceutical preparations in the nature of intravenous fluids used for the delivery of pharmaceutical preparations for novel apolipoprotein A-I infusion therapy to potentially reduce the risk of recurrent major adverse cardiovascular events, MACE, in patients within 90 days of an acute myocardial infarction, AMI, with a sustained benefit for 365 days; Pharmaceutical preparations for the treatment of acute myocardial infarction (AMI) being blood disorders; pharmaceutical preparations for treating of blood disorders and autoimmune diseases and disorders, namely, von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema (HAE), fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; Pharmaceutical preparations for the treatment and prevention of blood and blood bleeding disorders; pharmaceutical preparations for the treatment of hemophilia blood disorders; pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia blood disorders; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of blood diseases and disorders, respiratory diseases and disorders, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome (ARDS); pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and interstitial lung disease (ILD); Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema (HAE); Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema (HAE), respiratory diseases, acute respiratory distress syndrome (ARDS), Idiopathic Pulmonary Fibrosis (IPF) and interstitial lung disease (ILD);
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for cardiovascular diseases, illnesses, and conditions; Pharmaceutical preparations for infusion conditions; pharmaceutical preparations for cardiovascular conditions and blood conditions, namely, novel, plasma derived apolipoprotein A-I conditions while undergoing infusion therapy; pharmaceutical preparations for novel apolipoprotein A-I infusion therapy to potentially reduce the risk of recurrent major adverse cardiovascular events (MACE) in patients within 90 days of an acute myocardial infarction (AMI) with a sustained benefit for 365 days; Pharmaceutical preparations for acute myocardial infarction (AMI); Pharmaceutical preparations for cardiovascular diseases; pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of cardiovascular diseases, illnesses, and conditions; Pharmaceutical preparations for infusion conditions, namely cancers, autoimmune diseases, Crohn's disease, multiple sclerosis, serious infectious diseases, namely respiratory infections, eye infections, and severe dehydration; pharmaceutical preparations for the treatment of cardiovascular and blood disorders, namely, novel, plasma derived apolipoprotein A-I conditions while undergoing infusion therapy; pharmaceutical preparations in the nature of intravenous fluids used for the delivery of pharmaceutical preparations for novel apolipoprotein A-I infusion therapy to potentially reduce the risk of recurrent major adverse cardiovascular events, MACE, in patients within 90 days of an acute myocardial infarction, AMI, with a sustained benefit for 365 days; Pharmaceutical preparations for the treatment of acute myocardial infarction (AMI) being blood disorders; pharmaceutical preparations for treating of blood disorders and autoimmune diseases and disorders, namely, von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema (HAE), fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; Pharmaceutical preparations for the treatment and prevention of blood and blood bleeding disorders; pharmaceutical preparations for the treatment of hemophilia blood disorders; pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia blood disorders; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of blood diseases and disorders, respiratory diseases and disorders, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome (ARDS); pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and interstitial lung disease (ILD); Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema (HAE); Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema (HAE), respiratory diseases, acute respiratory distress syndrome (ARDS), Idiopathic Pulmonary Fibrosis (IPF) and interstitial lung disease (ILD);
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of cardiovascular diseases, illnesses, and conditions; Pharmaceutical preparations for infusion conditions, namely cancers, autoimmune diseases, Crohn's disease, multiple sclerosis, serious infectious diseases, namely respiratory infections, eye infections, and severe dehydration; pharmaceutical preparations for the treatment of cardiovascular and blood disorders, namely, novel, plasma derived apolipoprotein A-I conditions while undergoing infusion therapy; pharmaceutical preparations in the nature of intravenous fluids used for the delivery of pharmaceutical preparations for novel apolipoprotein A-I infusion therapy to potentially reduce the risk of recurrent major adverse cardiovascular events, MACE, in patients within 90 days of an acute myocardial infarction, AMI, with a sustained benefit for 365 days; Pharmaceutical preparations for the treatment of acute myocardial infarction (AMI) being blood disorders; pharmaceutical preparations for treating of blood disorders and autoimmune diseases and disorders, namely, von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema (HAE), fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; Pharmaceutical preparations for the treatment and prevention of blood and blood bleeding disorders; pharmaceutical preparations for the treatment of hemophilia blood disorders; pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia blood disorders; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of blood diseases and disorders, respiratory diseases and disorders, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome (ARDS); pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and interstitial lung disease (ILD); Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema (HAE); Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema (HAE), respiratory diseases, acute respiratory distress syndrome (ARDS), Idiopathic Pulmonary Fibrosis (IPF) and interstitial lung disease (ILD);
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for cardiovascular diseases, illnesses, and conditions; Pharmaceutical preparations for infusion conditions; pharmaceutical preparations for cardiovascular conditions and blood conditions, namely, novel, plasma derived apolipoprotein A-I conditions while undergoing infusion therapy; pharmaceutical preparations for novel apolipoprotein A-I infusion therapy to potentially reduce the risk of recurrent major adverse cardiovascular events, MACE, in patients within 90 days of an acute myocardial infarction, AMI, with a sustained benefit for 365 days; Pharmaceutical preparations for acute myocardial infarction, AMI, Pharmaceutical preparations for cardiovascular diseases; pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for cardiovascular diseases, illnesses, and conditions; Pharmaceutical preparations for infusion conditions; pharmaceutical preparations for cardiovascular conditions and blood conditions, namely, novel, plasma derived apolipoprotein A-I conditions while undergoing infusion therapy; pharmaceutical preparations for novel apolipoprotein A-I infusion therapy to potentially reduce the risk of recurrent major adverse cardiovascular events (MACE) in patients within 90 days of an acute myocardial infarction (AMI) with a sustained benefit for 365 days; Pharmaceutical preparations for acute myocardial infarction (AMI); Pharmaceutical preparations for cardiovascular diseases; pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for cardiovascular diseases, illnesses, and conditions; Pharmaceutical preparations for infusion conditions; pharmaceutical preparations for cardiovascular conditions and blood conditions, namely, novel, plasma derived apolipoprotein A-I conditions while undergoing infusion therapy; pharmaceutical preparations for novel apolipoprotein A-I infusion therapy to potentially reduce the risk of recurrent major adverse cardiovascular events, MACE, in patients within 90 days of an acute myocardial infarction, AMI, with a sustained benefit for 365 days; Pharmaceutical preparations for acute myocardial infarction, AMI; Pharmaceutical preparations for cardiovascular diseases; pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for cardiovascular diseases, illnesses, and conditions; Pharmaceutical preparations for infusion conditions; pharmaceutical preparations for cardiovascular conditions and blood conditions, namely, novel, plasma derived apolipoprotein A-I conditions while undergoing infusion therapy; pharmaceutical preparations for novel apolipoprotein A-I infusion therapy to potentially reduce the risk of recurrent major adverse cardiovascular events (MACE) in patients within 90 days of an acute myocardial infarction (AMI) with a sustained benefit for 365 days; Pharmaceutical preparations for acute myocardial infarction (AMI), Pharmaceutical preparations for cardiovascular diseases; pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD.
36 - Financial, insurance and real estate services
45 - Legal and security services; personal services for individuals.
Goods & Services
Administration of a program for financially needy populations for enabling participants to obtain financial assistance in the nature of discounts on goods and/or free product samples; Providing information regarding medical billing support services, namely, medical records coding services for others in the nature of assignment of diagnostic and procedural codes for purposes of reimbursement from insurance; Business administration of patient reimbursement programs Providing information regarding patient medication reimbursement programs and insurance coverage, namely, insurance reimbursement for immunoglobulin purchases Providing patient advocate and case management services, namely, coordinating the procurement and administration of medication; Providing personal support services for patients and families of patients, namely, emotional counseling and emotional support
The present invention relates to improved industrial scale processes for removing metal cations, such as copper, from blood plasma derived albumin products and pharmaceutical compositions derived therefrom. The albumin sample is contacted with a ligand for binding to or sequestering the metal cations, said ligand is a chelating agent, most preferably a biodegradable chelating agent, or a chelating resin, most preferably a cation-exchange chelating resin.
B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
A61P 7/08 - Plasma substitutesPerfusion solutionsDialytics or haemodialyticsDrugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 1/22 - Affinity chromatography or related techniques based upon selective absorption processes
41 - Education, entertainment, sporting and cultural services
Goods & Services
Educational services, namely, providing online instruction in the field of blood diseases, illnesses and conditions via an online website; Educational services, namely, developing, arranging, and conducting educational conferences and programs and providing courses of instruction in the field of blood diseases, illnesses and conditions; providing information for patients in the field of education about the stages of diseases, illnesses and medical conditions
69.
Immunoglobulin preparation and storage system for an immunoglobulin preparation
The present invention relates to an immunoglobulin preparation comprising immunoglobulin in a mass-volume percentage of at least 4%, wherein the concentration of oxygen dissolved in the preparation at room temperature is less than 40 μmol/l.
16 - Paper, cardboard and goods made from these materials
35 - Advertising and business services
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Printed materials, namely, newsletters, articles and case studies featuring immunoglobulin, immunodeficiency and neurological disorders; Printed publications, namely, brochures, booklets, newsletters, articles, case studies, and teaching materials in the field of immunoglobulin, immunodeficiency and neurological disorders; printed educational materials in the field of immunoglobulin, immunodeficiency and neurological disorders Healthcare education services, namely, promoting awareness of immunoglobulin, immunodeficiency and neurological disorders, its treatment and its impact on patients, patient families, caregivers and/or healthcare professionals to patients, caregivers and/or healthcare professionals Healthcare education services, namely, conducting educational programs for patients, caregivers and/or healthcare professionals concerning immunoglobulin, immunodeficiency and neurological disorders, its treatment and its impact on patients, patient families, caregivers and/or healthcare professionals; planning and conducting educational conventions and educational meetings related to immunoglobulin, immunodeficiency and neurological disorders, their treatment and their impact on patients, patient families, caregivers and/or healthcare professionals Providing a website featuring healthcare information in the field of immunoglobulin, immunodeficiency and neurological disorders, and corresponding treatments; Healthcare and healthcare information services, namely, providing information concerning immunoglobulin, immunodeficiency and neurological disorders, their treatment and their impact on patients, patient families, caregivers and/or healthcare professionals; Healthcare and healthcare information services, namely, providing information concerning patient lifestyle and wellness for patients, caregivers, parents, teachers, coaches and friends impacted by immunoglobulin, immunodeficiency and neurological disorders; Providing a website featuring information in the field of the diagnosis and treatment of immunoglobulin, immunodeficiency and neurological disorders; Providing links to the web sites of others featuring information about the diagnosis and treatment of immunoglobulin, immunodeficiency and neurological disorders
The present invention relates to a method and a system of extracting a protein with high yield from a protein-comprising precipitate, in particular immunoglobulin, from human or non-human origins, such as blood plasma.
The present disclosure relates to methods of purifying immunoglobulin G (IgG) and other proteins, such as albumin, from plasma or a fraction thereof using an affinity chromatography resin comprising a ligand capable of specifically binding to a CH3 domain of human IgG. The present disclosure also relates to formulation and uses of plasma protein product produced from the method.
The present disclosure relates to methods of purifying immunoglobulin G (IgG) and other proteins, such as albumin, from plasma or a fraction thereof using an affinity chromatography resin comprising a ligand capable of specifically binding to a CH3 domain of human IgG. The present disclosure also relates to formulation and uses of plasma protein product produced from the method.
The present invention relates to a method and system for extracting proteins from precipitates, particularly recombinant and/or plasma derived proteins including immunoglobulins (Ig) such as immunoglobulin G (IgG).
The present invention relates to a method for isolating plasminogen from a blood plasma fraction comprising dispersing a precipitate of a blood plasma fraction containing plasminogen in a basic aqueous buffer, separating solid parts thereof and removing at least parts of other proteins, and extracting the plasminogen with an acidic aqueous buffer.
The invention relates to a method for the purification of immunoglobulin and/or albumin from a sample of plasma, the method comprising mixing a sample of plasma with a medium chain fatty acid, and recovering the soluble immunoglobulin from the mixture.
The invention relates to a method for the purification of immunoglobulin and/or albumin from a sample of plasma, the method comprising mixing a sample of plasma with a medium chain fatty acid, and recovering the soluble immunoglobulin from the mixture.
The present invention relates to an expression system for producing a recombinant haptoglobin (Hp) beta chain, or a haemoglobin-binding fragment thereof, recombinant Hp molecules and uses thereof for treating and/or preventing a condition associated with cell-free haemoglobin (Hb).
The present invention relates to an expression system for producing a recombinant haptoglobin (Hp) beta chain, or a haemoglobin-binding fragment thereof, recombinant Hp molecules and uses thereof for treating and/or preventing a condition associated with cell-free haemoglobin (Hb).
The present disclosure relates generally to methods of treating or preventing an adverse secondary neurological outcome in a subject following a haemorrhagic stroke accompanied by extravascular erythrolysis and release of cell-free heme and/or cell-free haemoglobin (Hb) into a cerebral spinal fluid (CSF), the method comprising exposing the CSF of a subject in need thereof to a therapeutically effective amount of hemopexin (Hx) and for a period of time sufficient to allow the Hx to form a complex with, and thereby neutralise, the cell-free heme and, optionally, exposing the CSF of the subject to a therapeutically effective amount of haptoglobin (Hp) and for a period of time sufficient to allow the Hp to form a complex with, and thereby neutralise, the cell-free Hb.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
81.
METHOD OF TREATING OR PREVENTING AN ADVERSE SECONDARY NEUROLOGICAL OUTCOME FOLLOWING A HAEMORRHAGIC STROKE
The present disclosure relates generally to methods of treating or preventing an adverse secondary neurological outcome in a subject following a haemorrhagic stroke accompanied by extravascular erythrolysis and release of cell-free heme and/or cell-free haemoglobin (Hb) into a cerebral spinal fluid (CSF), the method comprising exposing the CSF of a subject in need thereof to a therapeutically effective amount of hemopexin (Hx) and for a period of time sufficient to allow the Hx to form a complex with, and thereby neutralise, the cell-free heme and, optionally, exposing the CSF of the subject to a therapeutically effective amount of haptoglobin (Hp) and for a period of time sufficient to allow the Hp to form a complex with, and thereby neutralise, the cell-free Hb.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical preparations and substances for immunoglobulin therapy, the treatment or prevention of primary or secondary immunodeficiencies, autoimmune disease and disorders, blood and/or bleeding disorders and diseases; Pharmaceuticals for the treatment or prevention of blood and/or bleeding disorders; Blood products, namely, blood plasma and blood for medical or therapeutic purposes; Blood products, namely, immunoglobulins for medical and therapeutic purposes; Blood proteins for therapeutic use Surgical and medical apparatus and instruments for the administration of subcutaneous therapy; Medical devices for the administration of subcutaneous therapy
83.
Process for preparing an immunoglobulin preparation
The present invention relates to the use of a CD91 polypeptide for detection and quantification of a hemopexin:heme complex in a biological sample, to the use of a CD91 polypeptide for separation of a hemopexin:heme complex from a biological sample and to the monitoring of a hemolysis treatment using a CD91 polypeptide.
The present invention relates to the use of a CD91 polypeptide for detection and quantification of a hemopexin:heme complex in a biological sample, to the use of a CD91 polypeptide for separation of a hemopexin:heme complex from a biological sample and to the monitoring of a hemolysis treatment using a CD91 polypeptide.
This invention is in the field of preventing or treating acute exacerbations in chronic lung diseases, such as chronic obstructive pulmonary disease and non-cystic fibrosis bronchiectasis, by administration of polyclonal immunoglobulin to the respiratory tract, in particular by direct application of an aerosolized composition comprising polyclonal immunoglobulin.
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Educational services in the field of health and treatment; Publication of the results of clinical trials. Providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Providing medical information and treatment information in the field of health, pharmaceuticals and clinical trials.
The present invention relates to a method and a system of extracting a protein with high yield from a protein-comprising precipitate, in particular immunoglobulin, from human or non-human origins, such as blood plasma.
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Educational services in the field of health and treatment; Publication of the results of clinical trials. Providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Providing medical information and treatment information in the field of health, pharmaceuticals and clinical trials.
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Educational services in the nature of training courses in the field of
health and treatment and distribution of educational materials in
connection therewith Providing scientific research information in the field of pharmaceuticals and clinical trials; providing information about medical research in the areas of health, pharmaceuticals and clinical trials Providing medical information and treatment information in the field of health, pharmaceuticals and clinical trials
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Educational services in the nature of training courses in the field of health and treatment and distribution of educational materials in connection therewith Providing scientific research information in the field of pharmaceuticals and clinical trials; providing information about medical research in the areas of health, pharmaceuticals and clinical trials Providing medical information and treatment information in the field of health, pharmaceuticals and clinical trials
The present invention relates to an immunoglobulin therapy. In particular, an immunoglobulin therapy for treating CIDP with non-axonal damage or mild axonal damage is provided.
The present invention relates to a method and system for extracting proteins from precipitates, particularly recombinant and/or plasma derived proteins including immunoglobulins (Ig) such as immunoglobulin G (IgG).
The present invention relates generally to methods for treating or preventing an adverse secondary neurological outcome in a subject following a haemorrhagic stroke accompanied by extravascular erythrolysis and release of cell-free haemoglobin (Hb) into a cerebral spinal fluid (CSF) comprising exposing the CSF of a subject in need thereof to a therapeutically effective amount of haptoglobin (Hp) and for a period of time sufficient to allow the Hp, or the functional analogue thereof, to form a complex with, and thereby neutralise, the cell-free Hb. Aspects of the invention further relate to compositions and kits of an artificial CSF comprising Hp.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 43/00 - Drugs for specific purposes, not provided for in groups
The present invention relates generally to a stable liquid formulation of purified hemopexin comprising: (a) a hemopexin content of at least 50 mg/mL; (b) at least 15 mM phosphate buffer; (c) a pH from 5.8 to 8; and (d) at least 50 mM sodium chloride; and uses thereof.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
96.
METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING ACUTE EXACERBATIONS WITH POLYCLONAL IMMUNOGLOBULIN
This invention is in the field of preventing or treating acute exacerbations in chronic lung diseases, such as chronic obstructive pulmonary disease and non-cystic fibrosis bronchiectasis, by administration of polyclonal immunoglobulin to the respiratory tract, in particular by direct application of an aerosolized composition comprising polyclonal immunoglobulin.
This invention is in the field of preventing or treating acute exacerbations in chronic lung diseases, such as chronic obstructive pulmonary disease and non-cystic fibrosis bronchiectasis, by administration of polyclonal immunoglobulin to the respiratory tract, in particular by direct application of an aerosolized composition comprising polyclonal immunoglobulin.
The present invention relates to an immunoglobulin preparation comprising immunoglobulin in a mass-volume percentage of at least 4%, wherein the concentration of oxygen dissolved in the preparation at room temperature is less than 40 μmol/l.
The present invention relates to immunoglobulin products for use in the treatment of chronic inflammatory demyelinating polyneuropathy using immunoglobulin products. In particular, the present invention provides efficacious dosing regimens.
The present invention relates to an immunoglobulin therapy. In particular, an immunoglobulin therapy for treating CIDP with non-axonal damage or mild axonal damage is provided.
